News

Dutch-Danish dermatology deal
Enlarge image

AntibodiesDenmarkNetherlands

Dutch-Danish dermatology deal

22.05.2015 - Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

Ballerup-based LEO Pharma will get access to one of arGEN-X’ antibodies, which is currently being developed for inflammation-related skin diseases. In return, arGEN-X will receive pre-IND payments of €4.5m, including an upfront payment, as well as milestone payments of up to €100m plus royalties. The allies will co-fund product development costs up to clinical trial application filing.

Breda-based arGEN-X N.V. develops therapeutic antibodies, and usually focuses on the treatment of cancer and severe autoimmune diseases. Danish LEO Pharma A/S, on the other hand, specialises in skin-related therapies, such as treatments for psoriasis and actinic keratosis. “We see huge potential in this new partnership in harnessing the complementary expertise of both companies: arGEN-X’ advanced knowledge and capabilities in therapeutic antibody development and LEO Pharma’s global expertise in bringing products to market that meet the needs of dermatology patients,” said Tim Van Hauwermeiren, Chief Executive Officer of arGEN-X. Added Thorsten Thormann, Senior Vice President, New Product Discovery at LEO Pharma: “Our alliance with arGEN-X is an important step forward as it marks our entry into the area of biotherapeutics for dermatology.”


© european-biotechnology-news.com/um

http://www.european-biotechnology-news.com/news/news/2015-02/danish-dutch-dermatology-deal.html

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/news/news.html?cHash=8190681cb0ea9c9ddcb48c4293a426da&sort=desc

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BASILEA133.60 CHF4.70%
  • WILEX4.21 EUR3.69%
  • STRATEC BIOMEDICAL48.52 EUR3.23%

FLOP

  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%

TOP

  • 4SC4.65 EUR263.3%
  • SYNGENTA422.00 CHF29.1%
  • WILEX4.21 EUR23.8%

FLOP

  • CYTOS0.63 CHF-42.7%
  • MEDIGENE8.58 EUR-32.4%
  • BIOTEST76.00 EUR-22.8%

TOP

  • WILEX4.21 EUR419.8%
  • CYTOS0.63 CHF350.0%
  • 4SC4.65 EUR322.7%

FLOP

  • MOLOGEN4.92 EUR-54.4%
  • BIOFRONTERA2.30 EUR-24.1%
  • CO.DON2.89 EUR-21.3%

No liability assumed, Date: 22.05.2015